Among 108 adults assigned to smoke CBD-dominant, THC-dominant or combined cannabis flower, higher peak THC levels were associated with a larger increase in a composite measure of inflammatory cytokines after use. Cannabis produced no measurable change in the study's insulin-sensitivity measure.
Why researchers tested this question
Cannabis can increase appetite, which would seem to point toward higher metabolic risk. At the same time, some observational research has linked cannabis use with lower rates of obesity or diabetes-related measures. Those correlations have encouraged theories that cannabinoids might affect inflammation or insulin sensitivity in beneficial ways. Our guide to THCA versus THC explains why heating cannabis changes which cannabinoid reaches the body.
The new study, published July 16 in Scientific Reports, tested an acute version of that theory. Researchers brought community participants into a mobile pharmacology laboratory and clinical research center, assigned cannabis flower by cannabinoid profile, measured blood cannabinoid levels and tracked inflammatory markers and insulin sensitivity. The peer-reviewed study and its ClinicalTrials.gov registration provide the full methods and prespecified trial record.
Higher THC exposure tracked with more inflammation
The researchers found a statistically significant interaction between time and peak blood THC. As peak THC levels increased, the composite pro-inflammatory cytokine measure increased more after cannabis use. The composite included TNF-alpha, IL-6, IL-1 beta, IL-12, interferon gamma and IL-4.
The immune response was not uniformly one-directional. Higher THC was also related to changes in IL-10, which is commonly described as anti-inflammatory, under certain CBD exposure conditions. MCP-1 decreased after use across the sample. The result is more complicated than saying cannabis is simply inflammatory or anti-inflammatory.
Insulin sensitivity did not improve
The study found no effect on the Matsuda Index, an insulin-sensitivity measure derived during an oral glucose tolerance test. That result does not prove cannabis worsens diabetes, but it failed to support the idea that acute cannabis use produces an immediate improvement in insulin sensitivity.
Observational findings can be influenced by diet, age, tobacco use, activity, socioeconomic factors and differences between people who use cannabis and those who do not. A controlled experiment helps isolate an immediate drug effect, but one session still cannot answer what repeated use does over months or years. That distinction also matters when reading broader evidence on cannabis and chronic pain.
This was quasi-randomized rather than fully randomized, participants smoked ad libitum, the sample was mostly white and the outcomes were acute. It did not test whether cannabis causes diabetes, prevents diabetes or changes cardiovascular outcomes. It also does not establish that one cytokine change translates into a clinical disease.
CBD did not produce a simple protective shield
The trial included CBD-dominant and combined products because consumers often hear that CBD balances THC. The observed interactions varied by marker and blood exposure. That does not support treating CBD as a blanket antidote to every physiological effect of THC.
The safest interpretation is narrow: higher THC exposure was associated with a stronger acute change in the pro-inflammatory composite, while insulin sensitivity did not measurably improve. More research is needed to connect those short-term biomarkers with actual disease risk. Potency alone is also a poor shortcut for quality, as our review of the higher-THC myth explains.
What consumers should take from it
People with diabetes, cardiovascular disease or inflammatory conditions should not use this study to start or stop treatment. Cannabis products are not approved substitutes for glucose management, anti-inflammatory therapy or preventive care. Discuss cannabis use with a clinician who knows your medications and health history.
For everyone else, the study is a reminder that a pleasant subjective effect and a favorable health effect are not the same thing. “Natural,” “hemp-derived” and “high potency” do not predict metabolic benefit.